Women's Health Diagnostics Market by Application (Prenatal Testing, Down Syndrome, HPV, Fertility Test, Pregnancy Test, Urinary Tract Infections, Osteoporosis, Breast, Cervical and Ovarian Cancer Test) End User (Hospitals, Home Care) - Forecast to 2021
出 版 商：MarketsandMarkets
出版日期：2016/11/25
頁 數：296頁
文件格式：PDF
價 格：
USD 5,650 (Single-User License)
USD 6,650 (Multi-User License)
USD 10,000 (Global-User License)
USD 6,650 (Multi-User License)
USD 10,000 (Global-User License)
Women's Health Diagnostics Market by Application (Prenatal Testing, Down Syndrome, HPV, Fertility Test, Pregnancy Test, Urinary Tract Infections, Osteoporosis, Breast, Cervical and Ovarian Cancer Test) End User (Hospitals, Home Care) - Forecast to 2021
The global women’s health diagnostics market is projected to reach USD 36.64 billion by 2021, growing at a CAGR of around 7.9% during the forecast period. Growth in this market can be attributed to a number of factors such as high prevalence of infectious diseases in women, rising incidence of chronic and lifestyle-related disorders and increasing awareness about fertility testing in women and initiatives taken by government and health organizations. Moreover, the increasing adoption of point-of-care diagnostic testing and the increasing number of diagnostic and imaging centers are also expected to play a major role in market growth. However, high cost of diagnostic solutions and lack of trained laboratory technicians are some of the factors restraining the growth of this market.
The women health diagnostics market in this report is segmented by application and end users. Based on application, the market is segmented into osteoporosis testing, ovarian cancer testing, cervical cancer testing, breast cancer testing, pregnancy & ovulation testing, prenatal genetic screening & carrier testing, infectious disease testing, sexually transmitted disease (STD) testing, and ultrasound. The osteoporosis segment is further divided into bone densitometry and in vitro blood tests. The ovarian cancer segment is divided into tumor marker tests, diagnostic imaging tests and others. The cervical cancer segment is sub segmented into PAP smear testing and HPV testing. The breast cancer testing segment is further divided into mammography systems, tumor marker tests, blood chemistries & blood cell count tests, biopsies, and other diagnostic imaging tests. Pregnancy and fertility testing market is sub segmented into lab-based testing, pregnancy self-test and ovulation prediction kits, ovulation prediction kits, fertility monitors and thermometers. The prenatal genetic screening & carrier testing segment is further divided into cystic fibrosis, Down syndrome and Edward syndrome, TORCH infections and others (fragile x-syndrome & tay-sachs diseases). Further on, the infectious disease testing market segment is sub segmented into methicillin-resistant staphylococcus aurea (MRSA), urinary tract infections (vaginal pH & vaginitis), hepatitis, tuberculosis and streptococcus testing. The sexually transmitted disease testing segment comprises Chlamydia Trachomatis and Neisseria Gonorrohoeae testing, HIV testing and other STD testing. The ultrasound segment covers breast imaging and ob/gyn imaging. In 2015, the breast cancer testing product segment accounted for the largest share of the women health diagnostics market. This market is primarily driven by the increasing incidence of breast cancer and rising awareness about advanced breast cancer diagnostic techniques. Based on end user, the women health diagnostics market is segmented into three segments, namely, hospitals & clinics, home care, and diagnostic & imaging centers.
In 2015, North America accounted for the largest share to the global women health diagnostics market, followed by Europe, Asia-Pacific, and the RoW. Growth in the North American market is largely driven by the increasing prevalence of cancer among women in this region, the presence of a large number of players and their increasing efforts to expand presence in North America. Furthermore, the increasing prevalence of cancer among women and increasing demand for fertility testing kits and monitors in North American countries is augmenting the demand for diagnostic tests.
Some of the major players in the women health diagnostics market are Siemens AG (Germany), Quest Diagnostics Inc. (U.S.), Hologic, Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), PerkinElmer Inc. (U.S.), Alere Inc. (U.S.), GE Healthcare (U.S.), Becton, Dickinson and Company (BD) (U.S.), Abbott Laboratories (U.S.), bioMerieux SA (France), and Koninklijke Philips N.V. (Netherlands).
Research Coverage
Detailed insights on all the submarkets, based on application (osteoporosis testing, ovarian cancer testing, cervical cancer testing, breast cancer testing, pregnancy & ovulation testing, prenatal genetic screening & carrier testing, infectious disease testing, sexually transmitted disease testing, and ultrasound), this can help market players to identify high growth segments in the women’s health diagnostics market.
The report also provides information on key players in this market and their growth strategies and recent developments. This can help the company to assess the competition at global and regional levels in a better manner.
Key insights and market sizing for the different end users of the women health diagnostics market namely, hospitals & clinics, home healthcare, and diagnostic & imaging centers.
Country-wise market size and forecast for all the sub segments. Thus, not only the high growth application and end user areas; the market size numbers provided in the report will also enable market players to identify key geographic markets, and thereby strategize global marketing efforts in order to achieve sustainable revenue growth in the coming years.
It provides key insights on market dynamics, such as drivers, restraints, opportunities, and challenges for this market.
Reasons to Buy the Report
The report will augment established firms as well as new entrants/smaller firms to measure the pulse of the market, which in turn would help them garner a greater market share. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for increasing their market shares.
This report provides insights on the following pointers:
‧ Market Penetration: Comprehensive information on product portfolios offered by top players in the women health diagnostics market. The report analyzes the women’s health diagnostics market by application, and end user across all regions
‧ Product Development/Innovation: Detailed insights on upcoming trends, research and development activities, and new product launches in the women health diagnostics market
‧ Market Development: Comprehensive information on the lucrative emerging markets by application, end user, and region
‧ Market Diversification: Exhaustive information of new products, growing regions, recent developments, and investments in the women health diagnostics market.
‧ Competitive Assessment: In-depth assessment of market shares, growth strategies, products, and distribution networks, of leading players in the women health diagnostics market
The global women’s health diagnostics market is projected to reach USD 36.64 billion by 2021, growing at a CAGR of around 7.9% during the forecast period. Growth in this market can be attributed to a number of factors such as high prevalence of infectious diseases in women, rising incidence of chronic and lifestyle-related disorders and increasing awareness about fertility testing in women and initiatives taken by government and health organizations. Moreover, the increasing adoption of point-of-care diagnostic testing and the increasing number of diagnostic and imaging centers are also expected to play a major role in market growth. However, high cost of diagnostic solutions and lack of trained laboratory technicians are some of the factors restraining the growth of this market.
The women health diagnostics market in this report is segmented by application and end users. Based on application, the market is segmented into osteoporosis testing, ovarian cancer testing, cervical cancer testing, breast cancer testing, pregnancy & ovulation testing, prenatal genetic screening & carrier testing, infectious disease testing, sexually transmitted disease (STD) testing, and ultrasound. The osteoporosis segment is further divided into bone densitometry and in vitro blood tests. The ovarian cancer segment is divided into tumor marker tests, diagnostic imaging tests and others. The cervical cancer segment is sub segmented into PAP smear testing and HPV testing. The breast cancer testing segment is further divided into mammography systems, tumor marker tests, blood chemistries & blood cell count tests, biopsies, and other diagnostic imaging tests. Pregnancy and fertility testing market is sub segmented into lab-based testing, pregnancy self-test and ovulation prediction kits, ovulation prediction kits, fertility monitors and thermometers. The prenatal genetic screening & carrier testing segment is further divided into cystic fibrosis, Down syndrome and Edward syndrome, TORCH infections and others (fragile x-syndrome & tay-sachs diseases). Further on, the infectious disease testing market segment is sub segmented into methicillin-resistant staphylococcus aurea (MRSA), urinary tract infections (vaginal pH & vaginitis), hepatitis, tuberculosis and streptococcus testing. The sexually transmitted disease testing segment comprises Chlamydia Trachomatis and Neisseria Gonorrohoeae testing, HIV testing and other STD testing. The ultrasound segment covers breast imaging and ob/gyn imaging. In 2015, the breast cancer testing product segment accounted for the largest share of the women health diagnostics market. This market is primarily driven by the increasing incidence of breast cancer and rising awareness about advanced breast cancer diagnostic techniques. Based on end user, the women health diagnostics market is segmented into three segments, namely, hospitals & clinics, home care, and diagnostic & imaging centers.
In 2015, North America accounted for the largest share to the global women health diagnostics market, followed by Europe, Asia-Pacific, and the RoW. Growth in the North American market is largely driven by the increasing prevalence of cancer among women in this region, the presence of a large number of players and their increasing efforts to expand presence in North America. Furthermore, the increasing prevalence of cancer among women and increasing demand for fertility testing kits and monitors in North American countries is augmenting the demand for diagnostic tests.
Some of the major players in the women health diagnostics market are Siemens AG (Germany), Quest Diagnostics Inc. (U.S.), Hologic, Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), PerkinElmer Inc. (U.S.), Alere Inc. (U.S.), GE Healthcare (U.S.), Becton, Dickinson and Company (BD) (U.S.), Abbott Laboratories (U.S.), bioMerieux SA (France), and Koninklijke Philips N.V. (Netherlands).
Research Coverage
Detailed insights on all the submarkets, based on application (osteoporosis testing, ovarian cancer testing, cervical cancer testing, breast cancer testing, pregnancy & ovulation testing, prenatal genetic screening & carrier testing, infectious disease testing, sexually transmitted disease testing, and ultrasound), this can help market players to identify high growth segments in the women’s health diagnostics market.
The report also provides information on key players in this market and their growth strategies and recent developments. This can help the company to assess the competition at global and regional levels in a better manner.
Key insights and market sizing for the different end users of the women health diagnostics market namely, hospitals & clinics, home healthcare, and diagnostic & imaging centers.
Country-wise market size and forecast for all the sub segments. Thus, not only the high growth application and end user areas; the market size numbers provided in the report will also enable market players to identify key geographic markets, and thereby strategize global marketing efforts in order to achieve sustainable revenue growth in the coming years.
It provides key insights on market dynamics, such as drivers, restraints, opportunities, and challenges for this market.
Reasons to Buy the Report
The report will augment established firms as well as new entrants/smaller firms to measure the pulse of the market, which in turn would help them garner a greater market share. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for increasing their market shares.
This report provides insights on the following pointers:
‧ Market Penetration: Comprehensive information on product portfolios offered by top players in the women health diagnostics market. The report analyzes the women’s health diagnostics market by application, and end user across all regions
‧ Product Development/Innovation: Detailed insights on upcoming trends, research and development activities, and new product launches in the women health diagnostics market
‧ Market Development: Comprehensive information on the lucrative emerging markets by application, end user, and region
‧ Market Diversification: Exhaustive information of new products, growing regions, recent developments, and investments in the women health diagnostics market.
‧ Competitive Assessment: In-depth assessment of market shares, growth strategies, products, and distribution networks, of leading players in the women health diagnostics market
TABLE OF CONTENTS
1 INTRODUCTION 22
1.1 OBJECTIVES OF THE STUDY 22
1.2 MARKET DEFINITION 22
1.3 MARKET SCOPE 23
1.3.1 MARKETS COVERED 23
1.3.2 YEARS CONSIDERED FOR THE STUDY 24
1.4 CURRENCY 25
1.5 LIMITATIONS 25
1.6 STAKEHOLDERS 25
2 RESEARCH METHODOLOGY 26
2.1 RESEARCH DATA 26
2.1.1 SECONDARY DATA 27
2.1.1.1 Key data from secondary sources 27
2.1.2 PRIMARY DATA 28
2.1.2.1 Key data from primary sources 28
2.1.2.2 Key industry insights 29
2.2 MARKET SIZE ESTIMATION 30
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 32
2.4 MARKET SHARE ESTIMATION 33
2.5 ASSUMPTIONS FOR THE STUDY 33
3 EXECUTIVE SUMMARY 34
4 PREMIUM INSIGHTS 37
4.1 WOMEN’S HEALTH DIAGNOSTICS: MARKET OVERVIEW 37
4.2 ASIA-PACIFIC: PREGNANCY AND FERTILITY TESTING MARKET, BY PRODUCT TYPE (2015) 38
4.3 GEOGRAPHIC SNAPSHOT OF THE WOMEN’S HEALTH DIAGNOSTICS MARKET 39
4.4 GEOGRAPGIC MIX: WOMEN’S HEALTH DIAGNOSTICS MARKET 40
4.5 WOMEN’S HEALTH DIAGNOSTICS MARKET: DEVELOPED VS. DEVELOPING MARKETS 41
5 MARKET OVERVIEW 42
5.1 INTRODUCTION 43
5.2 KEY MARKET DYNAMICS 44
5.2.1 KEY MARKET DRIVERS 45
5.2.1.1 High prevalence of infectious diseases in women 45
5.2.1.2 Rising incidence of chronic and lifestyle-related disorders in women 45
5.2.1.3 Increasing awareness about fertility testing in women and initiatives taken by government and health organizations 46
5.2.1.4 Increased adoption of point-of-care and rapid diagnostic tests 47
5.2.1.5 Growth in the number of private diagnostic and imaging centers 47
5.2.1.6 Public-private partnerships to enhance the infrastructure of diagnostic imaging centers 48
5.2.2 KEY MARKET RESTRAINTS 49
5.2.2.1 High cost of diagnostic imaging systems and procedures 49
5.2.2.2 Shortage of skilled laboratory technicians 49
5.2.3 KEY MARKET OPPORTUNITIES 50
5.2.3.1 Improving healthcare infrastructure in emerging markets 50
5.2.3.2 Growing number of regulatory approvals for immunoassay diagnostic techniques 51
5.2.4 KEY MARKET CHALLENGES 52
5.2.4.1 Stringent regulatory guidelines 52
5.2.4.2 Increasing adoption of refurbished diagnostic imaging systems 52
6 INDUSTRY INSIGHTS 53
6.1 INTRODUCTION 53
6.2 INDUSTRY TRENDS 54
6.2.1 GROWING FOCUS ON MICROFLUIDICS- AND NANOTECHNOLOGY-BASED POC DEVICES FOR DIAGNOSTICS 54
6.2.1.1 Microfluidics-based lab-on-a-chip (LOC) devices for laboratory testing 54
6.2.1.2 Evolution of paper-based microfluidic POC diagnostic devices 54
6.2.2 RISING FOCUS OF MARKET PLAYERS ON PREGNANCY AND FERTILITY ISSUES IN EMERGING REGIONS 55
6.3 CLINICAL TRIALS ASSESSMENT FOR BREAST CANCER DIAGNOSTICS 56
7 WOMEN’S HEALTH DIAGNOSTICS MARKET, BY APPLICATION 58
7.1 INTRODUCTION 59
7.2 OSTEOPOROSIS TESTING 61
7.2.1 BONE DENSITOMETRY 62
7.2.2 IN VITRO BLOOD TESTS 63
7.3 BREAST CANCER TESTING 64
7.3.1 MAMMOGRAPHY 67
7.3.2 BREAST CANCER TUMOR MARKER TESTS 68
7.3.3 BLOOD CHEMISTRIES AND BLOOD CELL COUNT TESTS 69
7.3.4 BIOPSIES 70
7.3.5 OTHER DIAGNOSTIC IMAGING TESTS 71
7.4 OVARIAN CANCER TESTING 72
7.4.1 OVARIAN CANCER TUMOR MARKER TESTS 73
7.4.2 DIAGNOSTIC IMAGING TESTS 75
7.4.3 OTHER TESTS 76
?
7.5 CERVICAL CANCER TESTING 77
7.5.1 PAP SMEAR 78
7.5.2 HPV TESTING 79
7.6 PREGNANCY AND FERTILITY TESTING 80
7.6.1 LAB-BASED TESTING 82
7.6.2 PREGNANCY TESTING AND OVULATION PREDICTION KITS 83
7.6.3 FERTILITY MONITORS 84
7.7 PRENATAL GENETIC SCREENING AND CARRIER TESTING 85
7.7.1 CYSTIC FIBROSIS 87
7.7.2 DOWN SYNDROME AND EDWARDS SYNDROME 88
7.7.3 TORCH INFECTIONS 89
7.7.4 OTHER DISEASES 90
7.8 INFECTIOUS DISEASE TESTING 91
7.8.1 MRSA TESTING 93
7.8.2 URINARY TRACT INFECTION TESTING (VAGINAL PH & VAGINITIS) 94
7.8.3 HEPATITIS TESTING 95
7.8.4 TUBERCULOSIS TESTING 96
7.8.5 OTHER INFECTIOUS DISEASES 98
7.9 SEXUALLY TRANSMITTED DISEASE TESTING 99
7.9.1 CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TESTING 100
7.9.2 HIV TESTING 101
7.9.3 OTHER SEXUALLY TRANSMITTED DISEASES 103
7.10 ULTRASOUND TESTS 104
7.10.1 BREAST IMAGING 105
7.10.2 OB/GYN IMAGING 106
8 WOMEN’S HEALTH DIAGNOSTICS MARKET, BY END USER 108
8.1 INTRODUCTION 109
8.2 HOSPITALS AND CLINICS 110
8.3 DIAGNOSTIC AND IMAGING CENTERS 112
8.4 HOME CARE 113
9 WOMEN’S HEALTH DIAGNOSTICS MARKET, BY REGION 115
9.1 INTRODUCTION 116
9.2 NORTH AMERICA 117
9.2.1 U.S. 125
9.2.2 CANADA 131
9.3 EUROPE 137
9.3.1 GERMANY 145
9.3.2 U.K. 151
9.3.3 FRANCE 157
9.3.4 ITALY 163
9.3.5 SPAIN 169
9.3.6 REST OF EUROPE 175
9.4 ASIA-PACIFIC 181
9.4.1 JAPAN 189
9.4.2 CHINA 195
9.4.3 INDIA 201
9.4.4 REST OF ASIA-PACIFIC 207
9.5 ROW 213
9.5.1 LATIN AMERICA 219
9.5.2 MIDDLE EAST & AFRICA 225
10 COMPETITIVE LANDSCAPE 232
10.1 OVERVIEW 232
10.2 STRATEGIC BENCHMARKING 233
10.3 COMPETITIVE SITUATIONS AND TRENDS 236
10.3.1 PRODUCT LAUNCHES 237
10.3.2 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS 238
10.3.3 ACQUISITIONS 239
10.3.4 REGULATORY APPROVALS 240
11 COMPANY PROFILES 241
(Overview, Products and Services, Financials, Strategy & Development)*
11.1 SIEMENS AG 241
11.2 QUEST DIAGNOSTICS INC. 245
11.3 HOLOGIC, INC. 253
11.4 F. HOFFMANN-LA ROCHE AG 258
11.5 PERKINELMER INC. 262
11.6 ALERE INC. 264
11.7 GE HEALTHCARE 266
11.8 BECTON, DICKINSON AND COMPANY 269
11.9 ABBOTT LABORATORIES 271
11.10 BIOMERIEUX SA 274
11.11 KONINKLIJKE PHILIPS N.V. 276
*Details on Overview, Products and Services, Financials, Strategy & Development might not be Captured in case of Unlisted Companies.
?
12 APPENDIX 279
12.1 INSIGHTS OF INDUSTRY EXPERTS 279
12.2 DISCUSSION GUIDE 280
12.3 OTHER DEVELOPMENTS 285
12.4 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 288
12.5 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 290
12.6 AVAILABLE CUSTOMIZATIONS 291
12.7 RELATED REPORTS 292
1 INTRODUCTION 22
1.1 OBJECTIVES OF THE STUDY 22
1.2 MARKET DEFINITION 22
1.3 MARKET SCOPE 23
1.3.1 MARKETS COVERED 23
1.3.2 YEARS CONSIDERED FOR THE STUDY 24
1.4 CURRENCY 25
1.5 LIMITATIONS 25
1.6 STAKEHOLDERS 25
2 RESEARCH METHODOLOGY 26
2.1 RESEARCH DATA 26
2.1.1 SECONDARY DATA 27
2.1.1.1 Key data from secondary sources 27
2.1.2 PRIMARY DATA 28
2.1.2.1 Key data from primary sources 28
2.1.2.2 Key industry insights 29
2.2 MARKET SIZE ESTIMATION 30
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 32
2.4 MARKET SHARE ESTIMATION 33
2.5 ASSUMPTIONS FOR THE STUDY 33
3 EXECUTIVE SUMMARY 34
4 PREMIUM INSIGHTS 37
4.1 WOMEN’S HEALTH DIAGNOSTICS: MARKET OVERVIEW 37
4.2 ASIA-PACIFIC: PREGNANCY AND FERTILITY TESTING MARKET, BY PRODUCT TYPE (2015) 38
4.3 GEOGRAPHIC SNAPSHOT OF THE WOMEN’S HEALTH DIAGNOSTICS MARKET 39
4.4 GEOGRAPGIC MIX: WOMEN’S HEALTH DIAGNOSTICS MARKET 40
4.5 WOMEN’S HEALTH DIAGNOSTICS MARKET: DEVELOPED VS. DEVELOPING MARKETS 41
5 MARKET OVERVIEW 42
5.1 INTRODUCTION 43
5.2 KEY MARKET DYNAMICS 44
5.2.1 KEY MARKET DRIVERS 45
5.2.1.1 High prevalence of infectious diseases in women 45
5.2.1.2 Rising incidence of chronic and lifestyle-related disorders in women 45
5.2.1.3 Increasing awareness about fertility testing in women and initiatives taken by government and health organizations 46
5.2.1.4 Increased adoption of point-of-care and rapid diagnostic tests 47
5.2.1.5 Growth in the number of private diagnostic and imaging centers 47
5.2.1.6 Public-private partnerships to enhance the infrastructure of diagnostic imaging centers 48
5.2.2 KEY MARKET RESTRAINTS 49
5.2.2.1 High cost of diagnostic imaging systems and procedures 49
5.2.2.2 Shortage of skilled laboratory technicians 49
5.2.3 KEY MARKET OPPORTUNITIES 50
5.2.3.1 Improving healthcare infrastructure in emerging markets 50
5.2.3.2 Growing number of regulatory approvals for immunoassay diagnostic techniques 51
5.2.4 KEY MARKET CHALLENGES 52
5.2.4.1 Stringent regulatory guidelines 52
5.2.4.2 Increasing adoption of refurbished diagnostic imaging systems 52
6 INDUSTRY INSIGHTS 53
6.1 INTRODUCTION 53
6.2 INDUSTRY TRENDS 54
6.2.1 GROWING FOCUS ON MICROFLUIDICS- AND NANOTECHNOLOGY-BASED POC DEVICES FOR DIAGNOSTICS 54
6.2.1.1 Microfluidics-based lab-on-a-chip (LOC) devices for laboratory testing 54
6.2.1.2 Evolution of paper-based microfluidic POC diagnostic devices 54
6.2.2 RISING FOCUS OF MARKET PLAYERS ON PREGNANCY AND FERTILITY ISSUES IN EMERGING REGIONS 55
6.3 CLINICAL TRIALS ASSESSMENT FOR BREAST CANCER DIAGNOSTICS 56
7 WOMEN’S HEALTH DIAGNOSTICS MARKET, BY APPLICATION 58
7.1 INTRODUCTION 59
7.2 OSTEOPOROSIS TESTING 61
7.2.1 BONE DENSITOMETRY 62
7.2.2 IN VITRO BLOOD TESTS 63
7.3 BREAST CANCER TESTING 64
7.3.1 MAMMOGRAPHY 67
7.3.2 BREAST CANCER TUMOR MARKER TESTS 68
7.3.3 BLOOD CHEMISTRIES AND BLOOD CELL COUNT TESTS 69
7.3.4 BIOPSIES 70
7.3.5 OTHER DIAGNOSTIC IMAGING TESTS 71
7.4 OVARIAN CANCER TESTING 72
7.4.1 OVARIAN CANCER TUMOR MARKER TESTS 73
7.4.2 DIAGNOSTIC IMAGING TESTS 75
7.4.3 OTHER TESTS 76
?
7.5 CERVICAL CANCER TESTING 77
7.5.1 PAP SMEAR 78
7.5.2 HPV TESTING 79
7.6 PREGNANCY AND FERTILITY TESTING 80
7.6.1 LAB-BASED TESTING 82
7.6.2 PREGNANCY TESTING AND OVULATION PREDICTION KITS 83
7.6.3 FERTILITY MONITORS 84
7.7 PRENATAL GENETIC SCREENING AND CARRIER TESTING 85
7.7.1 CYSTIC FIBROSIS 87
7.7.2 DOWN SYNDROME AND EDWARDS SYNDROME 88
7.7.3 TORCH INFECTIONS 89
7.7.4 OTHER DISEASES 90
7.8 INFECTIOUS DISEASE TESTING 91
7.8.1 MRSA TESTING 93
7.8.2 URINARY TRACT INFECTION TESTING (VAGINAL PH & VAGINITIS) 94
7.8.3 HEPATITIS TESTING 95
7.8.4 TUBERCULOSIS TESTING 96
7.8.5 OTHER INFECTIOUS DISEASES 98
7.9 SEXUALLY TRANSMITTED DISEASE TESTING 99
7.9.1 CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) TESTING 100
7.9.2 HIV TESTING 101
7.9.3 OTHER SEXUALLY TRANSMITTED DISEASES 103
7.10 ULTRASOUND TESTS 104
7.10.1 BREAST IMAGING 105
7.10.2 OB/GYN IMAGING 106
8 WOMEN’S HEALTH DIAGNOSTICS MARKET, BY END USER 108
8.1 INTRODUCTION 109
8.2 HOSPITALS AND CLINICS 110
8.3 DIAGNOSTIC AND IMAGING CENTERS 112
8.4 HOME CARE 113
9 WOMEN’S HEALTH DIAGNOSTICS MARKET, BY REGION 115
9.1 INTRODUCTION 116
9.2 NORTH AMERICA 117
9.2.1 U.S. 125
9.2.2 CANADA 131
9.3 EUROPE 137
9.3.1 GERMANY 145
9.3.2 U.K. 151
9.3.3 FRANCE 157
9.3.4 ITALY 163
9.3.5 SPAIN 169
9.3.6 REST OF EUROPE 175
9.4 ASIA-PACIFIC 181
9.4.1 JAPAN 189
9.4.2 CHINA 195
9.4.3 INDIA 201
9.4.4 REST OF ASIA-PACIFIC 207
9.5 ROW 213
9.5.1 LATIN AMERICA 219
9.5.2 MIDDLE EAST & AFRICA 225
10 COMPETITIVE LANDSCAPE 232
10.1 OVERVIEW 232
10.2 STRATEGIC BENCHMARKING 233
10.3 COMPETITIVE SITUATIONS AND TRENDS 236
10.3.1 PRODUCT LAUNCHES 237
10.3.2 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS 238
10.3.3 ACQUISITIONS 239
10.3.4 REGULATORY APPROVALS 240
11 COMPANY PROFILES 241
(Overview, Products and Services, Financials, Strategy & Development)*
11.1 SIEMENS AG 241
11.2 QUEST DIAGNOSTICS INC. 245
11.3 HOLOGIC, INC. 253
11.4 F. HOFFMANN-LA ROCHE AG 258
11.5 PERKINELMER INC. 262
11.6 ALERE INC. 264
11.7 GE HEALTHCARE 266
11.8 BECTON, DICKINSON AND COMPANY 269
11.9 ABBOTT LABORATORIES 271
11.10 BIOMERIEUX SA 274
11.11 KONINKLIJKE PHILIPS N.V. 276
*Details on Overview, Products and Services, Financials, Strategy & Development might not be Captured in case of Unlisted Companies.
?
12 APPENDIX 279
12.1 INSIGHTS OF INDUSTRY EXPERTS 279
12.2 DISCUSSION GUIDE 280
12.3 OTHER DEVELOPMENTS 285
12.4 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 288
12.5 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 290
12.6 AVAILABLE CUSTOMIZATIONS 291
12.7 RELATED REPORTS 292
